#United States #Robbins Geller #San Diego #Class Action #Baxter International

Baxter International Class Action Lawsuit Alert

The law firm Robbins Geller Rudman & Dowd LLP has announced a significant opportunity for investors of Baxter International Inc. (NYSE: BAX). If you purchased or acquired common stock of Baxter between February 23, 2022, and July 30, 2025, you may have the chance to become a lead plaintiff in a class action lawsuit against the company. The deadline for submitting your application is December 15, 2025.

Background of the Case

The lawsuit, titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., is filed under case number 25-cv-12672 in the Northern District of Illinois. Investors allege that Baxter, along with several of its former and current executives, violated the Securities Exchange Act of 1934 during the specified Class Period. The class action claims that the defendants made misleading statements and failed to properly disclose critical issues regarding the Novum IQ Large Volume Pump (Novum LVP).

Allegations Against Baxter International

Among the key allegations are:
1. Device Defects: Baxter's Novum LVP reportedly suffered from systemic defects, which led to widespread malfunctions such as underinfusion, overinfusion, and even total failure to deliver fluids. Such defects exposed patients to severe risks, including potential injury or death.
2. Inadequate Disclosure: The lawsuit claims that Baxter was aware of several device malfunctions resulting in patient injuries and fatalities, yet failed to adequately inform investors and the public.
3. Insufficient Measures Taken: It is alleged that Baxter's attempts to mitigate these defects through customer alerts were too weak in addressing the ongoing design issues.
4. Market Reaction: After Baxter disclosed on July 31, 2025, that it would pause shipments and installations related to the Novum LVP, its stock price plummeted by over 22%.

The Lead Plaintiff Role

Under the Private Securities Litigation Reform Act of 1995, any investor who acquired Baxter’s common stock during the Class Period has the right to seek the role of lead plaintiff in the ongoing class action. A lead plaintiff is someone who has the highest financial stake in the outcome of the case and serves as a representative for all class members. The lead plaintiff role allows the investor to choose a legal representation firm to pursue the lawsuit. Importantly, an investor's entitlement to any potential recovery is independent of their status as the lead plaintiff.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is recognized as a leader in securities fraud and shareholder litigation. They have a strong history, securing significant financial recoveries for investors in various securities-related class action suits. In fact, the firm recovered more than $2.5 billion for investors in 2024 alone, making it a leading force in the field of investor representation. They have earned high accolades, including being ranked #1 in the ISS Securities Class Action Services for securing monetary relief for investors the most times in recent years.

Next Steps for Investors

If you suffered substantial losses during the Class Period and wish to participate as a lead plaintiff in this class action lawsuit, it’s essential to act promptly. You may submit your information through the official Robbins Geller website or directly contact attorneys within the firm for guidance. This could be an opportunity not only to reclaim financial losses but also to hold Baxter accountable for their alleged misconduct.

For further assistance, reach out to J.C. Sanchez or Jennifer N. Caringal from Robbins Geller by calling 800-449-4900 or via email at [email protected].

Stay informed and take the necessary steps while there’s still time to seek justice and financial redress from Baxter International.